Effects of glucagon-like peptide-1 receptor agonists on kidney function and safety in type 2 diabetes patients

J Diabetes Investig. 2021 Jun;12(6):914-916. doi: 10.1111/jdi.13552. Epub 2021 May 7.

Authors

Min Kyung Kim¹, Doo-Man Kim¹

Affiliation

¹ Division of Endocrinology, Department of Internal Medicine, Hallym University College of Medicine, Kangdong Sacred Heart Hospital, Seoul, Korea.

Abstract

Glucagon-like peptide-1 receptor agonists have been recommended in diabetic kidney disease patients.

© 2021 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.

Publication types

Review

MeSH terms

Diabetes Mellitus, Type 2 / complications
Diabetes Mellitus, Type 2 / drug therapy*
Diabetic Nephropathies / etiology
Diabetic Nephropathies / prevention & control*
Glomerular Filtration Rate / drug effects
Glucagon-Like Peptide-1 Receptor / agonists*
Humans
Hypoglycemic Agents / pharmacology*
Kidney / drug effects*
Sodium-Glucose Transporter 2 Inhibitors / pharmacology

Substances

Glucagon-Like Peptide-1 Receptor
Hypoglycemic Agents
Sodium-Glucose Transporter 2 Inhibitors